FİB

PreclinicalSmall molecule

MMedipol University

FİB is one of 7 small molecule programs targeting Aortic Valve Stenosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic Valve StenosisRecruiting

Aortic Valve StenosisPreclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Aortic Valve Stenosis

#DrugCompanyPhaseTrials

Brilinta

AstraZeneca

Approved

1 2

Colcrys

Jazz Pharmaceuticals

Phase 3

1 3

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 4

Vascepa

AAmarin Pharma Inc.

Phase 2

1 5

Ataciguat

Sanofi

Preclinical

2 6

FİB

MMedipol University

Preclinical

1 7

Local Infiltration

TThe Catholic University of Korea

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Aortic Valve Stenosis

NCT06773780

Clinical

Trials by Indication[1]

Aortic Valve Stenosis1 trial

Transcatheter Aortic Valve Implantation: Comparison of the Effects of Ultrasound-Guided Pericapsular Nerve Group Block and Fascia Iliaca Block on Postoperative Analgesia Management - A Randomized, Prospective Study

Recruiting·MMedipol University·Preclinical·NCT06773780·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FİB. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FİB compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FİB. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medipol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedipol University

FİB

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Aortic Valve Stenosis1 trial

References

Drug Info

Quick Facts

Related News